AdamDCohenMD

PubMed

• 1 citations
  Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy.
  Yan Tang, Wei Liu, Siddhant Kadu, Omar Johnson, Zainul S Hasanali, Andre Kelly, Alexander Shestov, Raymone Pajarillo, Eli Greenblatt, Matthew Holmes, Li-Ping Wang, Nat...> ;Blood. 2024 Jan 11
• Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
  Zainul S Hasanali, Beatrice Razzo, Sandra P Susanibar-Adaniya, Alfred L Garfall, Edward A Stadtmauer, Adam D Cohen> ;Hematology/oncology Clinics of North America. 2024 Apr 1
• Options at the time of relapse after anti-BCMA therapy.
  Razzo, B., Garfall, A., Cohen, A.> ;Hematology. American Society of Hematology. Education Program. 2023 Dec 8
• Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulking.
  Christopher Ghiathi, Ashley N Barlev, Gabriel C Caponetti, John P Plastaras, Devraj Basu, Adam D Cohen, Kevin C Ma> ;Clinical Case Reports. 2023 Nov 1
• 7 citations
  Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
  Morie A Gertz, Adam D Cohen, Raymond L Comenzo, Efstathios Kastritis, Heather J Landau, Edward N Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashu...> ;Blood. 2023 Oct 5
• 2 citations
  Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
  Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Natalie Callander, Al-Ola Abdallah, Suzanne Trudel, Ajai Chari, Edward N Libby, Maria Chau...> ;Cancer. 2023 Dec 1
• 2 citations
  Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
  Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja, Saad Z Usmani, Mounzer Agha, Carolyn C Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Dec 1
• Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
  Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud, Sundar Jagannath> ;Future Oncology. 2023 Jun 1
• 4 citations
  Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
  Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Lee Smol...> ;Oncology and Therapy. 2023 Jun 1
• 44 citations
  Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
  Adam D Cohen, María-Victoria Mateos, Yael C Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W C J van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C De Braganc...> ;Blood. 2023 Jan 19
• 15 citations
  Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
  Taxiarchis Kourelis, Radhika Bansal, Jesus Berdeja, David Siegel, Krina Patel, Sham Mailankody, Myo Htut, Nina Shah, Sandy W Wong, Surbhi Sidana, Andrew J Cowan, Melis...> ;Transplantation and Cellular Therapy. 2023 Apr 1
• 2 citations
  Progressive multifocal leukoencephalopathy in multiple myeloma.
  Brian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, Sandra P Susanibar-Adaniya, Dan T Vogl, Adam J Waxman, Mark Bardsley, Samantha Le, Lexis LaMaestra, Alfred L Garfall> ;European Journal of Haematology. 2023 Mar 1
• 12 citations
  Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
  Alfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, Wei-Ting Hwang, Dan T Vogl, Adam J Waxman, Simon F Lacey, Vanessa E Gonzalez, Joseph A Fraietta, Minnal Gup...> ;Blood Cancer Discovery. 2023 Mar 1
• 3 citations
  Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the ...
  Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D Goldberg, Jordan M Schecter, Carolyn C Jackson, Kath...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jan 1
• 10 citations
  Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
  Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, A Keith Stewart, Parameswaran Hari, Jesus G Berdeja, Saad Z Usmani, Tzu-Min Yeh, Yunsi Olyslager, Jenna D ...> ;The Lancet. Haematology. 2022 Dec 1
• 26 citations
  Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
  Kavita M Dhodapkar, Adam D Cohen, Akhilesh Kaushal, Alfred L Garfall, Renee Julia Manalo, Allison R Carr, Samuel S McCachren, Edward A Stadtmauer, Simon F Lacey, J Jos...> ;Blood Cancer Discovery. 2022 Nov 2
• 127 citations
  Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
  Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial, Noopur S Raje, Eva Medvedova, Philip L McCarthy, Edward N Libby, Peter M Voorhees, Rob...> ;The New England Journal of Medicine. 2022 Jul 14
• 139 citations
  Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
  Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C Munshi...> ;Journal of Clinical Oncology. 2023 Feb 20
• 3 citations
  CAR T cell therapy for multiple myeloma: What have we learned?
  Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen> ;Leukemia. 2022 Jun 1
• 62 citations
  Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
  Adam D Cohen, Samir Parekh, Bianca D Santomasso, Jaime Gállego Pérez-Larraya, Niels W C J van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carol...> ;Blood Cancer Journal. 2022 Feb 24
• 41 citations
  Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
  Noopur S Raje, Elias Anaissie, Shaji K Kumar, Sagar Lonial, Thomas Martin, Morie A Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O'Donnell, Andrew...> ;The Lancet. Haematology. 2022 Feb 1
• 2 citations
  Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
  Daniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, Andrew Chow, Levi Mangarin, Adam D. Cohen, Linda Hamadene, Sadna Budhu, Nathan Suek, Cailian Liu, Alan N. Hou...> ;JCI Insight. 2021 Oct 22
• 13 citations
  The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma.
  Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, R.J.L. Maxwell, W. Tristram Arscott, Amit Maity, Joshua Jones, John P. Plastara...> ;Clinical Cancer Research. 2021 Sep 15
• 6 citations
  A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients.
  Muzaffar H. Qazilbash, Neeraj Saini, Cha Soung-chul, Zhe Wang, Edward A. Stadtmauer, Veerabhadran Baladandayuthapani, Heather Lin, Beryl Tross, Medhavi Honhar, Sheetal...> ;Blood. 2021 Sep 14
• 82 citations
  Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
  Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al-Ola Abdallah, Natalie S. Callander, Douglas W. Sborov, Attaya Suvannasankha, Ka...> ;Cancer. 2021 Jul 27
• Join now to see all

Abstracts/Posters

• First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to El...
  Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
  Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
  Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
  Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
  Adam D. Cohen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Immunotherapy in Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• CAR-T and Cellular Therapy in Myeloma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
• Join now to see all